Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2023 Nov 28;11(11):e007667.
doi: 10.1136/jitc-2023-007667.

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)

Benedetta Pellegrino #  1   2 , Chiara Tommasi #  1   2 , Olga Serra  2 , Stefania Gori  3 , Elisabetta Cretella  4 , Massimo Ambroggi  5 , Antonio Frassoldati  6 , Giancarlo Bisagni  7 , Chiara Casarini  8 , Emilio Bria  9   10 , Luisa Carbognin  10   11 , Elena Fiorio  11 , Antonella Mura  12 , Claudio Zamagni  13 , Lorenzo Gianni  14 , Alberto Zambelli  15 , Filippo Montemurro  16 , Michele Tognetto  17 , Renata Todeschini  17 , Gabriele Missale  18 , Nicoletta Campanini  1 , Enrico Maria Silini  1 , Giuseppe Maglietta #  19 , Antonino Musolino #  20   2
Affiliations
Clinical Trial

Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016)

Benedetta Pellegrino et al. J Immunother Cancer. .

Abstract

Background: It is possible to induce immunomodulation in HER2-positive breast cancer (BC) by modifying the route of administration of trastuzumab.

Methods: In this multicenter randomized phase II trial, all enrolled patients (pts) with T2-T4d HER2-positive BC received 3 cycles of neoadjuvant treatment (NAT) with fluorouracil, epirubicin and cyclophosphamide every 3 weeks (q21), followed by docetaxel/pertuzumab plus intravenous trastuzumab (arm A) or, docetaxel/pertuzumab plus subcutaneous (SC) trastuzumab (arm B) q21x4 cycles. After surgical operation, each pt was treated with trastuzumab q21x14 cycles using the same SC or intravenous formulation of NAT. Primary endpoint was the proportion of subjects with high stromal tumor-infiltrating lymphocytes (sTILs) in postneoadjuvant residual disease (RD).

Results: Sixty-three pts (31 (arm A) and 32 (arm B)) were enrolled. Pathological complete response was obtained by 20/31 pts (64.5%; 95% CI 45.4% to 80.1%) in arm A and 19/32 pts (59.4%; 95% CI 40.1% to 76.3%) in arm B. High sTILs were observed in 27% and 46% of postneoadjuvant residual tumors in arms A and B, respectively. CD8+ T cells increased significantly in RDs of both arms (p=0.014 and 0.002 for arm A and B, respectively), whereas a significant decline in the level of CD4+ FoxP3+ regulatory T cells was observed only in arm B (p=0.016). A significant upregulation of PD-1 on sTILs was found in RD of pts enrolled in arm B (p=0.012), while programmed death-ligand 1 (PD-L1) was significantly overexpressed in residual tumors of arm A (p=0.02). A strong negative correlation was reported in arm B between expression of PD-L1 on pretreatment sTILs and CD3 expression on sTILs in RD (τ: -0.73). Grade≥3 AE incidence rates were similar between the two arms.

Conclusions: SC trastuzumab induced relevant sTILs enrichment, with favorable variations of immune parameters in HER2-positive BC pts with RD after NAT. Novel immunotherapy strategies should be tested to achieve SC-specific, antitumor immune response.

Trial registration number: NCT03144947, and EudraCT number: 2016-000435-41.

Keywords: adaptive Immunity; antibodies, neoplasm; breast neoplasms.

PubMed Disclaimer

Conflict of interest statement

Competing interests: BP reports research grants from Lilly, Pfizer, Novartis; and personal fees from MSD outside the submitted work. EC reports travel grants from Pfizer and Ipsen outside the submitted work. EB reports research grants from Roche, AstraZeneca; personal fees from MSD, AstraZeneca, BMS, Roche, Novartis, Pfizer, Lilly; and travel grants from Roche and AstraZeneca outside the submitted work. LC reports personal fees from AstraZeneca, Novartis and Lilly outside the submitted work. LG reports personal fees from Daiichi, Seagen; and travel grants from Ipsen, Novartis, Pfizer outside the submitted work. AZ reports personal fees from AstraZeneca, Lilly, Pfizer, Daiichi, MSD, Roche, Seagen, Exact Sciences, Gilead and Istituto Gentili outside the submitted work. FM reports personal fees from Roche, Novartis, AstraZeneca, Daiichi, Seagen, MSD, Lilly, Pfizer, Pierre Fabre; and travel grants from Roche and AstraZeneca outside the submitted work; from May 15th 2023, FM is Roche employee. AM reports research grants from Lilly; personal fees from Seagen, Daiichi, Gilead, Novartis, AstraZeneca; and travel grants from Gilead and Novartis outside the submitted work.

Figures

Figure 1
Figure 1
Flowchart for Simon’s two-stage design. SC, subcutaneous; sTILs, stromal tumor-infiltrating lymphocytes.
Figure 2
Figure 2
Boxplot showing stromal tumor-infiltrating lymphocytes (sTILs) levels in pretreatment tumor biopsies of patients enrolled in arms A and B. The actual median level of sTILs was 7.5% for all enrolled patients, with no difference between the two study arms.
Figure 3
Figure 3
Significant changes in stromal tumor-infiltrating lymphocytes (sTILs) from pretreatment tumor biopsy to postneoadjuvant residual disease in matched paired samples (by study arm). (A) Total sTILs. (B) CD8+ T cells. (C) CD4+ FoxP3+ regulatory T cells (Tregs). (D) PD-1+ sTILs and PD-L1+ cells (tumor, lymphocytes and macrophages; combined positive score (CPS) score ≥1%).
Figure 4
Figure 4
Matrix showing Kendall’s correlation coefficients for all the possible pairs of tumor-infiltrating lymphocyte immunophenotypes in pretreatment tumor biopsies and postneoadjuvant residual diseases, by study arm.
Figure 5
Figure 5
Boxplots showing pretreatment stromal tumor-infiltrating lymphocyte (sTIL) levels in pathological complete response (pCR) versus non-pCR patients. (A), All enrolled patients. (B), By study arm.
See this image and copyright information in PMC

References

    1. Slamon DJ, Clark GM, Wong SG, et al. . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82. 10.1126/science.3798106 - DOI - PubMed
    1. Musolino A, Boggiani D, Pellegrino B, et al. . Role of innate and adaptive immunity in the efficacy of anti-HER2 Monoclonal antibodies for Her2-positive breast cancer. Crit Rev Oncol Hematol 2020;149:102927. 10.1016/j.critrevonc.2020.102927 - DOI - PubMed
    1. Gianni L, Pienkowski T, Im Y-H, et al. . Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (Neosphere): a randomised Multicentre, open-label, phase 2 trial. Lancet Oncol 2012;13:25–32. 10.1016/S1470-2045(11)70336-9 - DOI - PubMed
    1. Piccart M, Procter M, Fumagalli D, et al. . Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years' follow-up. J Clin Oncol 2021;39:1448–57. 10.1200/JCO.20.01204 - DOI - PubMed
    1. Slamon DJ, Eiermann W, Robert NJ, et al. . Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and Trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2+ early breast cancer. Cancer Res 2016;76:S5–04. 10.1158/1538-7445.SABCS15-S5-04 - DOI

Publication types

Associated data